Insulet Corporation (PODD) - Total Liabilities
Based on the latest financial reports, Insulet Corporation (PODD) has total liabilities worth $1.68 Billion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PODD cash flow conversion to assess how effectively this company generates cash.
Insulet Corporation - Total Liabilities Trend (2002–2025)
This chart illustrates how Insulet Corporation's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Insulet Corporation to evaluate the company's liquid asset resilience ratio.
Insulet Corporation Competitors by Total Liabilities
The table below lists competitors of Insulet Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ningbo Zhoushan Port Co Ltd
SHG:601018
|
China | CN¥30.31 Billion |
|
Sitime Corporation
NASDAQ:SITM
|
USA | $138.52 Million |
|
Jiangsu Etern Co Ltd
SHG:600105
|
China | CN¥5.75 Billion |
|
Vietnam JSCmmercial Bank for Industry and Trade
VN:CTG
|
Vietnam | ₫2588.06 Trillion |
|
Skanska AB (publ)
ST:SKA-B
|
Sweden | Skr96.34 Billion |
|
Wynn Resorts Limited
NASDAQ:WYNN
|
USA | $14.53 Billion |
|
Max Healthcare Institute Limited
NSE:MAXHEALTH
|
India | Rs62.29 Billion |
|
Samsara Inc
NYSE:IOT
|
USA | $1.12 Billion |
Liability Composition Analysis (2002–2025)
This chart breaks down Insulet Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PODD company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Insulet Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Insulet Corporation (2002–2025)
The table below shows the annual total liabilities of Insulet Corporation from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.68 Billion | -10.71% |
| 2024-12-31 | $1.88 Billion | +1.11% |
| 2023-12-31 | $1.86 Billion | +4.55% |
| 2022-12-31 | $1.77 Billion | +18.91% |
| 2021-12-31 | $1.49 Billion | +17.58% |
| 2020-12-31 | $1.27 Billion | +18.96% |
| 2019-12-31 | $1.07 Billion | +48.89% |
| 2018-12-31 | $716.64 Million | +8.87% |
| 2017-12-31 | $658.23 Million | +67.28% |
| 2016-12-31 | $393.50 Million | +63.23% |
| 2015-12-31 | $241.07 Million | +10.42% |
| 2014-12-31 | $218.33 Million | +33.65% |
| 2013-12-31 | $163.36 Million | +6.16% |
| 2012-12-31 | $153.88 Million | +11.36% |
| 2011-12-31 | $138.19 Million | +53.54% |
| 2010-12-31 | $90.00 Million | -24.24% |
| 2009-12-31 | $118.79 Million | +13.18% |
| 2008-12-31 | $104.95 Million | +172.85% |
| 2007-12-31 | $38.47 Million | -75.79% |
| 2006-12-31 | $158.91 Million | +91.72% |
| 2005-12-31 | $82.88 Million | +15.71% |
| 2004-12-31 | $71.63 Million | +101.16% |
| 2003-12-31 | $35.61 Million | -1.54% |
| 2002-12-31 | $36.16 Million | -- |
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain… Read more